(Q38016943)

27 August 2017

0 references

Impact of the UGT1A1*28 allele on response to irinotecan: a systematic review and meta-analysis (English)

1 reference

27 August 2017

0 references

0 references

1 reference

1 reference

Mafalda M Dias

1

1 reference

27 August 2017

Ross A McKinnon

series ordinal

2

1 reference

27 August 2017

Michael J Sorich

series ordinal

3

1 reference

27 August 2017

language of work or name

English

0 references

publication date

1 June 2012

1 reference

27 August 2017

1 reference

27 August 2017

volume

13

1 reference

27 August 2017

issue

8

1 reference

27 August 2017

page(s)

889-899

1 reference

Can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan? An evidence-based review

27 August 2017

cites work

1 reference

Dose-dependent association between UGT1A1*28 polymorphism and irinotecan-induced diarrhoea: a meta-analysis

21 January 2018

1 reference

Dose-dependent association between UGT1A1*28 genotype and irinotecan-induced neutropenia: low doses also increase risk

21 January 2018

1 reference

UGT1A and irinotecan toxicity: keeping it in the family

21 January 2018

1 reference

Irinotecan and uridine diphosphate glucuronosyltransferase 1A1 pharmacogenetics: to test or not to test, that is the question

21 January 2018

1 reference

Molecular predictive and prognostic markers in colon cancer

21 January 2018

1 reference

Recommendations from the EGAPP Working Group: can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan?

21 January 2018

1 reference

Cost effectiveness of pharmacogenetic testing for uridine diphosphate glucuronosyltransferase 1A1 before irinotecan administration for metastatic colorectal cancer.

21 January 2018

1 reference

Cost-effectiveness of UGT1A1 genotyping in second-line, high-dose, once every 3 weeks irinotecan monotherapy treatment of colorectal cancer.

21 January 2018

1 reference

Predictive biomarkers of chemotherapy efficacy in colorectal cancer: results from the UK MRC FOCUS trial

21 January 2018

1 reference

Pharmacogenetic assessment of toxicity and outcome in patients with metastatic colorectal cancer treated with LV5FU2, FOLFOX, and FOLFIRI: FFCD 2000-05.

21 January 2018

1 reference

UGT1A1*28 genotype and irinotecan dosage in patients with metastatic colorectal cancer: a Dutch Colorectal Cancer Group study.

21 January 2018

1 reference

Pharmacogenetic predictors of adverse events and response to chemotherapy in metastatic colorectal cancer: results from North American Gastrointestinal Intergroup Trial N9741.

21 January 2018

1 reference

UGT1A and TYMS genetic variants predict toxicity and response of colorectal cancer patients treated with first-line irinotecan and fluorouracil combination therapy

21 January 2018

1 reference

Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFIRI chemotherapy

21 January 2018

1 reference

The UGT1A1*28 genotype and the toxicity of low-dose irinotecan in patients with advanced lung cancer

21 January 2018

1 reference

Prediction of irinotecan and 5-fluorouracil toxicity and response in patients with advanced colorectal cancer

21 January 2018

1 reference

Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124.

21 January 2018

1 reference

UGT1A1*28 polymorphism predicts irinotecan-induced severe toxicities without affecting treatment outcome and survival in patients with metastatic colorectal carcinoma

21 January 2018

1 reference

UGT1A1 gene polymorphism: impact on toxicity and efficacy of irinotecan-based regimens in metastatic colorectal cancer

21 January 2018

1 reference

Clinical significance of UDP-glucuronosyltransferase 1A1*6 for toxicities of combination chemotherapy with irinotecan and cisplatin in gynecologic cancers: a prospective multi-institutional study

21 January 2018

1 reference

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

21 January 2018

1 reference

The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration

21 January 2018

1 reference

Meta-analysis of Observational Studies in Epidemiology: A Proposal for Reporting

21 January 2018

1 reference

Methodological quality of pharmacogenetic studies: issues of concern

21 January 2018

1 reference

Predictive role of the UGT1A1, UGT1A7, and UGT1A9 genetic variants and their haplotypes on the outcome of metastatic colorectal cancer patients treated with fluorouracil, leucovorin, and irinotecan.

21 January 2018

1 reference

Assessing tumor response to therapy

21 January 2018

1 reference

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis

21 January 2018

1 reference

Weekly regimen of irinotecan/docetaxel in previously treated non-small cell lung cancer patients and correlation with uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) polymorphism

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.2217/PGS.12.68

1 reference

27 August 2017

1 reference